Menu Search
Equities

CG Oncology Inc

CGON:NSQ

CG Oncology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.47
  • Today's Change1.13 / 3.49%
  • Shares traded404.18k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year CG Oncology Inc had net income fall 37.14% from a loss of 35.44m to a larger loss of 48.61m despite a 6.81% increase in revenues from 191.00k to 204.00k. An increase in the selling, general and administrative costs as a percentage of sales from 3,354.97% to 4,853.43% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin-10,578.22%
Operating margin-13,969.15%
Return on assets-18.93%
Return on equity-36.52%
Return on investment-19.63%
More ▼

Cash flow in USDView more

In 2023, cash reserves at CG Oncology Inc fell by 79.88m. Cash Flow from Financing totalled 87.00m or 42,645.59% of revenues. In addition the company used 45.68m for operations while cash used for investing totalled 121.20m.
Cash flow per share-1.19
Price/Cash flow per share--
Book value per share7.95
Tangible book value per share7.95
More ▼

Balance sheet in USDView more

CG Oncology Inc uses little or no debt in its capital structure.
Current ratio35.32
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.